NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Thanks for examining this theory of the 13 LTF in such detail for all of us. I had to read your post several times (well, I was rushing and skipping stuff the first few times)I order to take it all in, but ultimately, your argument that they removed those thirteen and that they were from the “vanguard” group was made very clearly; and I suspect you’re correct.

What I’m wondering is why remove these LTF patients from the final analysis, as you make the case that this obviously handicapped the results when comparing the treatment arm to the ECA. You’ve obviously spent considerable time in analyzing this, so do you perhaps also have a theory as to why they may have remove those patients from the first 19 months?